Abstract. Dendritic cells (DCs) have been used in a number of clinical trials for cancer immunotherapy; however, they have achieved limited success in solid tumors. Consequently the aim of the present study was to identify a novel potential immunotherapeutic target for breast cancer patients through in vitro optimization of a viable DC-based vaccine. Immature DCs were primed by viable MCF-7 breast cancer cells and the activity and maturation of DCs were assessed through measuring CD83, CD86 and major histocompatibility complex ( 
Introduction
Breast cancer is the second-leading cause of cancer-associated mortality among women worldwide (1) and constitutes 22.9% of cancer cases in women (2) . In Egypt, it was reported that breast cancer represented ~38.2% of female malignancies (3) . Despite advancements in treatment strategies, metastatic breast cancer remains incurable, with available therapies predominantly aiming to provide symptomatic relief and extend the overall survival time of the patient (4) .
The development of effective vaccines for specific tumor cell antigens is uncomplicated; however, this approach has achieved limited success in solid tumors, particularly in the case of breast cancer (5) . This is due to the number of breast cancer cell subgroups, which vary in morphology, biology, behavior and response to therapy (5) . Constructing an effective, reliable, tolerable and safe cancer vaccine is the core principle of cancer immunotherapy. Dendritic cells (DCs) are critical players in producing an antitumor immune response and have been employed as a cellular cancer vaccine in a number of clinical trials (6, 7) . Using DCs provides a unique immune response against tumor-associated antigens (TAAgs); therefore, DC-based vaccines are capable of regulating and maintaining T cell functions that generate an effective cellular immune response (8, 9) .
The present study was designed to construct a potential breast cancer vaccine in which DCs were primed by intact viable cancer cells. This strategy is advantageous in that the cancer cells provide a full complement of TAAgs, including major histocompatibility complex (MHC) class I and class II-restricted epitopes, and can provoke an immune response against numerous unknown tumor antigens and may therefore A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell-dendritic cell-based vaccine (10, 11) . The mononuclear cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin for 24 h in a humidified incubator at 37˚C with 5% CO 2 . The non-adherent cells (lymphocytes) were removed by gently washing with pre-warmed (37˚C) tissue culture medium containing recombinant human interleukin (IL)-2 (2 ng/ml). The adherent cells (monocytes) were cultured in RPMI-1640 medium containing recombinant human cytokines, granulocyte monocyte-colony stimulating factor (GM-CSF) and IL-4 (700 and 500 IU/ml, respectively; Koma Biotech Inc., Seoul, South Korea), thereby producing immature DCs.
Immature DC (IDC) loading with MCF-7 breast cancer cells.
On day 5 of culture, IDCs were co-cultured with MCF-7 breast cancer cells for 24 h at a ratio of 10:1 in RPMI-1640 medium with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified incubator at 37˚C with 5% CO 2 to generate mature DCs (MDCs).
T cell priming by autologous MDCs. Lymphocytes were counted and added to the flask of co cultured MDCs and MCF-7 cell line at ratio of (lymphocytes: DCs; 10:1) for 2 days. The count was estimated upon characterization of DCs using a flow cytometer and confirmed using a hemocytometer. Foxp3 was prepared using an IntaPrep permeabilization kit (Beckman Coulter, Inc., Brea, CA, USA). Intracellular staining was performed using IntaPrep permeabilization reagent, by which cells were fixed with reagent 1 (fixation reagent using formaldehyde). Following washing, cells were permeabilized using reagent 2 (using Saponine for permeability). Buffer was supplied from a Foxp3/Transcription Factor Staining Buffer Set (00-5523; eBioscience; Thermo Fisher Scientific. Inc., Waltham, MA, USA). Samples were analyzed using a flow cytometer (NAVIOS; Beckman Coulter, Inc., Figs. 1 and 2).
Detection of cytotoxicity produced by activated CTLs.
Cytotoxicity was assessed by measuring LDH release from the MCF-7 breast cancer cell line prior to and following co culture with CTL for 2 days, using an ELISA (cat no. SEB864Hu, Cloud-Clone Corp., Katy, TX, USA) according to the manufacturer's protocol. T cells were added to the population of tumor cells and DCs in the same flask to ensure that antigen presentation, T cell activation and exposure to tumor cells occurred simultaneously in order to mimic what occurs in the tumor microenvironment, and allow interactions with different cytokines. This was a preliminary step for immunotherapy preparation.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay of FOXP3 gene expression in CTLs.
RNA was purified from samples using the SV Total RNA Isolation System (Promega Corporation, Madison, WI, USA), and cDNA was produced using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.), conducted according to the manufacturer's protocols. Two primer sets were designed to eliminate the possibility of primer dimer formation and nonspecific annealing using Primer3 (version 4.0; http://bioinfo.ut.ee/primer3-0.4.0/) and oligoanalyzer 3. Biosystems; Thermo Fisher Scientific, Inc.). The RT-qPCR amplification products were analyzed via melting curve analysis. The relative expression of gene transcripts was calculated according to the ΔCq and 2 -ΔΔCq formulas according to Schmittgen and Livak (13) . Finally, the ratios of target to reference gene were determined with the Pfaffl method (14) .
Statistical analysis. Statistical analysis was conducted using SPSS version 24 (IBM Corp., Armonk, NY, USA). Data are expressed as the mean ± SEM. Comparison between groups was performed using paired Student's t-test for comparison between variables prior to and following activation. Pearson correlation analysis was applied for quantitative variables. P<0.05 was considered to indicate a statistically significant difference.
Results

DC activation and maturation ex vivo by exposure to tumor antigens of viable breast cancer cells.
The present study was conducted on 30 patients with breast cancer and 15 control healthy females with mean ages of 53.9±10.9 and 50±9.4 years, respectively (Table I ). CD83 and CD86 were significantly increased on DCs isolated from breast cancer patients and healthy controls (P<0.001) following loading with viable MCF breast cancer cells for 24 h (Fig. 3) .
Activation of CTLs. The activation of T lymphocytes was
confirmed by the upregulation of CD4, CD8 and CD3, detected by flow cytometric analysis. Significant increases in the levels of CD4 + T-helper (Th) cells and CD8 + CTLs were observed (P<0.001; Fig. 4A and B) . However, there was a significant decrease in the CD4 + CD25 +bright Foxp3 + regulatory T cell (Treg) subpopulation (P<0.001) isolated from breast cancer patients and healthy controls following activation with MDCs previously loaded with whole viable MCF-7 cells (Fig. 4C and D) .
Cytokine detection by ELISA. The effect of priming DCs with viable MCF-7 breast cancer cells resulted in a significant increase in IL-12 secretion in the media of DCs from breast cancer patients and healthy controls (P<0.001). Furthermore, activation of Th cells by the vaccine resulted in a significant elevation in the IFN-γ level in the media of T cells isolated from breast cancer patients and healthy controls (P= 0.001; Fig. 5A and B) . This was confirmed by the significant association between the IL-12 and IFN-γ levels (P<0.05; r= 0.399). IL-12 also positively correlated with LDH (P<0.05; r=0.418). There was a significant decrease in Foxp3 released in the media of T cells isolated from breast cancer patients and healthy controls (P<0.001) following activation with MDCs previously loaded with whole viable cancer cells (Fig. 5C ).
Detection of CTL cytotoxicity. There was a significant elevation in LDH release in the media of MCF-7 cells following mixing with CTLs induced by the whole viable cancer cell-primed DCs (P<0.001; Fig. 5D ). 
RT-qPCR for
Discussion
A number of studies have been conducted to enhance the antitumor immune response in breast cancer through priming DCs; however, selecting and optimizing the antigen-loading strategy has been demonstrated to be a challenging undertaking (6, 8, 15) . The most common method is by using freeze-thawed ordinary lysates that are obtained by subjecting cancer cells to several freeze and thaw cycles using liquid nitrogen and water baths (16, 17) . However, DCs loaded with such lysates have not provided complete protection against tumor responses in differential animal models (16, 18, 19) . Furthermore, in clinical trials, numerous studies have demonstrated that freeze-thawed lysates are ineffective for therapy as they suppress DC maturation and function (17, 20, 21) . The present study attempted to optimize tumor antigen loading with DCs by a novel strategy. This was obtained by subjecting DCs isolated from breast cancer patients, or healthy controls as a comparison, to intact viable MCF-7 cells in complete conditioned RPMI-1640 medium. The activation of DCs was demonstrated by significantly increased levels of the stimulatory molecule CD86, maturation molecule CD83 and MHC-II. The elevation of such molecules may enhance the capacity of DCs to prime T cell responses. By contrast, other studies have used DCs loaded with cell culture supernatants that may not have contained sufficient or adequate antigens secreted in the media (22) . Additionally, a previous study demonstrated reduced levels of CD80, CD86 and CD40 in DCs loaded with irradiated tumor cells (23) . Another important feature of mature active DCs is the production of IL-12. In the present study, there was a significant increase in its secretion, from 160.03±10.27 pg/ml prior to activation to 254.60±12.67 pg/ml following activation of DCs with viable tumor antigens. IL-12 has a crucial importance in the differentiation of naive T cells into Th cells and subsequently in initiating an active specific immune response through the induction of IFN-γ and tumor necrosis factor-α from T cells and natural killer cells, as demonstrated by Vieira et al (24) .
The results of the present study revealed that the interaction of viable cancer cells and DCs resulted in stimulation of CD4 + Th cells and CD8 + CTLs against a wide range of tumor antigens. This was confirmed by the increased expression of CD4 + , CD8
+ and CD3 + cells by flow cytometry, as well the increased secretion of IFN-γ by reactive tumor antigen-specific CD4 + Th cells. An explanation for these findings is that these cells were capable of inducing IFN-γ and TNF-α, and serve a role in priming tumor-specific CTLs through the release of IL-2 (25) . These results suggested that DC priming by whole, intact tumor cells induced a differential MHC class I and II cross-presentation of tumor antigen to T cells, as reported by Kini Bailur et al (26) , and therefore induced a potent antitumor immune response.
Furthermore Tregs, which are increased in the blood and tumor microenvironment of patients with breast cancer compared with healthy subjects (27, 28) and its level is correlated with advanced clinical stages (29) . Previous studies have emphasized the role of Tregs in the suppression of antitumor immune responses, as they are considered to exhibit critical functions in the progression and modulation of immunological escape mechanisms in malignancies. These cells express FOXP3 and CTL-associated protein-4 (CTLA-4), as negative regulatory molecules of active immune cells, and are increased in breast cancer patients (30, 31) . Increased expression of Foxp3 and subsequently Tregs are considered obstacles that may hinder the desired response of potential immune therapeutic strategies (30) (31) (32) . Therefore, in the present study the level of Foxp3 protein secreted in the media of cultured T lymphocytes from breast cancer patients was assessed, which demonstrated a significant decrease in Foxp3 following the subjection of T cells to tumor cell-primed DCs (P<0.001). This was confirmed by a significant downregulation of Foxp3 gene expression in CTLs as detected by RT-qPCR. Furthermore a significant upregulation of Foxp3 gene expression (~12-fold higher) was observed in peripheral blood of patients compared with normal healthy controls, which was consistent with the results of Hamidinia et al (33) . This was also confirmed by the inverse correlation between FOXP3 gene expression and CD4 + Th cell levels identified in the peripheral blood of the patients enrolled in the present study. These findings suggested that the immune system was suppressed in breast cancer patients, which may be due to an augmentation in the Treg population and suppression of effector Th cells.
An alternative way to assess the efficacy of the viable cancer cell-DC based vaccine was through the detection of cytotoxicity exerted by activated CTLs on MCF-7 cells through the measurement of LDH release. The results demonstrated a significant increase in LDH level, indicting a highly active and potent immune response against these cancer cells. As described by Faloppi et al (34) , LDH is typically released from necrotic cells. Therefore, the higher the degree of necrosis, which is related to tumor volume, the higher the level of LDH. It is important to clarify that a significant positive correlation was identified between IL-12 produced by this type of viable cancer cell-based vaccine and the increased level of IFN-γ, also, IL-12 was positively correlated with increased cytotoxicity and necrosis of tumor cells via the increased level of LDH. Therefore, the current study has identified an avenue for further studying the development of novel effective immunotherapy for patients suffering from breast cancer using DCs.
In summary, the current study demonstrated that a viable cancer cells are an effective source of TAAs for pulsing DCs, which may be utilized in the immunotherapeutic treatment of breast cancer. The matured DCs induced expansion of TAA-specific T cells, namely CTLs and Th cells. A strong cytokine response was provoked through increased IFN-γ and IL-12 levels. Additionally, an augmentation of the immune response was indicated by decreased Tregs and Foxp3 expression, and an elevation of CTL activity, as indicated by an increase in LDH release.
